Trials soon ready
Clinical trials expected to report results within the next 3 months, ranked by potential. Each trial shows its estimated finish date — explained in plain language.
Showing the top 50 of 63 trials in this window.
-
Can a bone marrow trick make face transplants safer?
⭐️ CURE ⭐️ Recruiting nowBackground: The human face is critically important for breathing, eating, seeing, and speaking/ communicating, but its most important job may be to look like a human face. Devastating facial deformities often cause affected individuals to avoid human contact and disappear from so…
Results expected Aug 2026 (estimated)
Phase: PHASE2 • Sponsor: Johns Hopkins University • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
Can a One-Two punch of CAR-T and lenalidomide beat tough leukemia?
⭐️ CURE ⭐️ Recruiting nowThis is a Phase I/II interventional, open-label treatment study designed to evaluate the safety and efficacy of concomitant therapy with anti-CD19 CAR T-cells and Lenalidomide in adult patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who have been pretreated w…
Results expected Aug 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Vitebsk Regional Clinical Cancer Centre • Aim: ⭐️ CURE ⭐️
Last updated Aug 15, 2026 00:00 UTC
-
Could a stem cell transplant cure immune diseases?
⭐️ CURE ⭐️ Recruiting nowBackground: During a transplant, blood stem cells from one person are given to someone else. The cells grow into the different cells that make up the immune system. This can cure people with certain immunodeficiencies. But transplant has many risks and complications. Objective:…
Results expected Oct 2026 (estimated)
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 12:28 UTC
-
Can engineered immune cells outsmart Hard-to-Treat blood cancers?
⭐️ CURE ⭐️ OngoingThe purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Results expected Oct 2026 (estimated)
Phase: PHASE1 • Sponsor: Arcellx, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
Gilead Sciences, Inc. · GILD NASDAQ Trade on eToro (ad)Reward if it works Very highAiming at a cure or vaccine; success would transform the company.
Risk to the company ModerateA small company — one failure carries real weight.
-
Could a Virus-Like particle vaccine outsmart polio?
⭐️ VACCINE ⭐️ OngoingThis is a phase I/II randomized, double-blind, and positive-controlled study. Participants in the phase I toddler group will receive 1 dose of either high dose VLP-Polio (Dose H) or control vaccine in a ratio of 3:1. The phase I infant cohort will have 4 arms randomly assigned to…
Results expected Oct 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: CanSino Biologics Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 08, 2026 00:03 UTC
CanSino Biologics Inc. · 6185 HKEXReward if it works Very highAiming at a cure or vaccine; success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
Can specially trained immune cells flush out hidden HIV?
⭐️ CURE ⭐️ OngoingThis is a multi-site phase 1 study of the safety, immunologic and virologic responses of ex vivo expanded donor-derived (DD) HIV-1 multi-antigen specific T-cell (HST) with non-escaped epitope targeting (NEET) therapy as a therapeutic strategy in HIV-infected individuals following…
Results expected Nov 2026 (estimated)
Phase: PHASE1 • Sponsor: Catherine Bollard • Aim: ⭐️ CURE ⭐️
Last updated Aug 16, 2026 00:00 UTC
-
New COVID-19 vaccine candidate tested alone or as a booster with mRNA shots
⭐️ VACCINE ⭐️ Recruiting nowThe main purposes of this research study are to measure the safety (whether it causes any side effects), tolerability (if it does cause any side effects, how well your body is able to handle them), and reactions, both local at the injection site and systemic, that may occur in th…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Invivyd, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:00 UTC
InVivyd · IVVD NASDAQ Trade on eToro (ad) -
New chikungunya vaccine trial aims to protect millions
⭐️ VACCINE ⭐️ Recruiting nowA Seamless Phase II/III, Observer-blind, Multi-centre, Randomized Clinical Trial to Evaluate Immunogenicity and Safety of BBV87, an Inactivated Chikungunya Virus Vaccine in Healthy Subjects 12-65 Years of Age
Results expected Sep 2026 (estimated)
Phase: PHASE2, PHASE3 • Sponsor: Bharat Biotech International Limited • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:24 UTC
-
Engineered immune cells take aim at Mesothelioma—Can they deliver?
⭐️ CURE ⭐️ OngoingThis study will test the safety of MSLN-targeted CAR-T cells at different doses to find the safest dose to give to people with MPM. The researchers want to see what effects, if any, the study treatment has on people with this type of cancer. This study is the first time that an M…
Results expected Sep 2026 (estimated)
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: ⭐️ CURE ⭐️
Last updated Jul 29, 2026 00:00 UTC
-
New marburg vaccine trial aims to stop deadly virus
⭐️ VACCINE ⭐️ OngoingA Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
Results expected Oct 2026 (estimated)
Phase: PHASE2 • Sponsor: Albert B. Sabin Vaccine Institute • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:14 UTC
-
New RSV vaccine candidate aims to shield older adults from severe lung infections
⭐️ VACCINE ⭐️ Recruiting nowThis Phase I/II study is to characterize the safety and immunogenicity of 2 dose levels of AZD6489, an investigational RSV recombinant prefusion F protein VLP vaccine.
Results expected Oct 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 23, 2026 00:00 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Reward if it works HighAiming at a cure or vaccine; success would still be major news.
Risk to the company Very lowA large company running many trials — it absorbs a failure here.
-
New needle treatment could replace surgery for curing Hormone-Driven high blood pressure
⭐️ CURE ⭐️ OngoingThe primary objective of WAVE is to test the hypothesis that thermal ablation (microwave or RFA) is non-inferior to surgery in the biochemical (and if so, in the clinical) cure of unilateral PA, according to the international consensus PASO criteria. Secondary objectives are to …
Results expected Nov 2026 (estimated)
Phase: NA • Sponsor: Queen Mary University of London • Aim: ⭐️ CURE ⭐️
Last updated Jul 19, 2026 00:00 UTC
-
Could two HPV shots be enough for women with HIV?
⭐️ VACCINE ⭐️ Recruiting nowThere are very little data on human papillomavirus (HPV) vaccination among the 18 million women living with HIV (WLWH) globally, who constitute a population most vulnerable to HPV and the resultant cervical cancer. Particularly, there are no data to date on reduced-dose schedules…
Results expected Aug 2026 (estimated)
Phase: PHASE4 • Sponsor: University of British Columbia • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:02 UTC
-
New shingles vaccine shows promise in Head-to-Head trial
⭐️ VACCINE ⭐️ OngoingThe goal of this clinical trial is to assess the safety and immunogenicity of an srRNA-based vaccine, JCXH-105, in the prevention of Herpes Zoster (Shingles). Subjects will be randomized to receive either JCXH-105 or Shingrix.
Results expected Aug 2026 (estimated)
Phase: PHASE2 • Sponsor: Immorna Biotherapeutics, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:23 UTC
-
New COVID vaccine trial targets healthy Middle-Aged adults
⭐️ VACCINE ⭐️ OngoingThe purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of the COVID-19 vaccine, mRNA-1273, in adults aged 50-64 years without known risk factors for severe COVID-19 infection. Participants will be randomized 1:1 to either COVID-19 vaccine or no CO…
Results expected Aug 2026 (estimated)
Phase: PHASE4 • Sponsor: Tor Biering-Sørensen • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 11:02 UTC
-
New yellow fever vaccine trial for kids could boost global protection
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of this study is to determine whether vYF (investigational vaccine) is safe and can help the body to develop antibodies (immunogenicity) compared with Stamaril vaccine and YF-VAX vaccine (both licensed vaccines) and when they are co-administered with Measles Mumps Rub…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
Sanofi · SNY NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Could this vaccine stop future coronavirus pandemics?
⭐️ VACCINE ⭐️ OngoingCoronaviruses (CoVs) have caused the severe acute respiratory syndrome (SARS) outbreak, the Middle East Respiratory Syndrome (MERS) outbreak, and now the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Although there are several approved or authorized vacci…
Results expected Aug 2026 (estimated)
Phase: PHASE1 • Sponsor: Duke University • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:06 UTC
-
New RSV vaccine trial targets High-Risk adults in japan
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of the study is to learn about the immune response after a RSVpreF vaccination. This study is being conducted in Japan. RSV is a common virus that can cause infections of the lungs and airways. The study is seeking participants who are: * 18 to 59 years of age * adu…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:00 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Can a genetically modified oral vaccine beat cholera?
⭐️ VACCINE ⭐️ Recruiting nowCholera is a serious diarrheal disease that can be fatal within hours of onset. The current available cholera vaccines to prevent the disease are not very effective. Panchol is a new oral cholera vaccine that may be an improvement over the currently available vaccines in use. The…
Results expected Aug 2026 (estimated)
Phase: PHASE1 • Sponsor: Centre for Infectious Disease Research in Zambia • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 31, 2026 00:00 UTC
-
New vaccines aim to block malaria transmission in africa
⭐️ VACCINE ⭐️ OngoingAssessing the safety, immunogenicity and ex-vivo efficacy of two transmission blocking vaccines (Pfs25-IMX313 in Matrix M and Pfs48/45 in Matrix M alone and co-administered) in Burkina Faso, in 18-45 years, 12-17 years and 05-11 year olds.
Results expected Sep 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:08 UTC
-
New RSV vaccine trial aims to protect vulnerable transplant recipients
⭐️ VACCINE ⭐️ OngoingAdjuvant, non-live RSV vaccine will be administered to adult lung and allogeneic hematopoietic stem cell transplant recipients. The safety and immunogenicity of this intervention will be studied. Blood work will be collected before and after the intervention, to assess humoral an…
Results expected Sep 2026 (estimated)
Phase: PHASE3 • Sponsor: University Health Network, Toronto • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:28 UTC
-
New 24-Valent vaccine aims to shield children from more pneumonia strains
⭐️ VACCINE ⭐️ Recruiting nowA Phase 2 clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in the pediatric population aged 2 months (minimum 42 days) to 5 years. The objective of the study is to evaluate the safety and immunogenici…
Results expected Sep 2026 (estimated)
Phase: PHASE2 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:06 UTC
Sinovac Biotech Ltd. · SVA NASDAQReward if it works ModerateAiming at a cure or vaccine; success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New vaccine aims to shield against deadly meningitis strains
⭐️ VACCINE ⭐️ Recruiting nowPhase 2/3 study to evaluate immunogenicity and safety in healthy adult participants following a single dose administration of Meningococcal (groups A, C, W-135, and Y) conjugate vaccine
Results expected Sep 2026 (estimated)
Phase: PHASE2, PHASE3 • Sponsor: EyeGene Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:00 UTC
-
Cancer vaccine aims to prevent leukemia relapse in older adults
⭐️ VACCINE ⭐️ OngoingThis research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML). The interventions involved in this study are: -Dendritic Cell/AML Fusion vaccine (DC/AML vaccine)
Results expected Sep 2026 (estimated)
Phase: PHASE2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:01 UTC
-
New shingles vaccine trial aims to protect millions over 40
⭐️ VACCINE ⭐️ OngoingThe objective of this study was to evaluate the safety, immunogenicity and immune persistence of recombinant herpes zoster vaccine (CHO cells) with different adjuvant doses in healthy people aged 40 years and older.
Results expected Sep 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Ab&B Bio-tech Co., Ltd.JS • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:01 UTC
-
MRNA technology takes on the stomach flu: moderna launches norovirus vaccine trial
⭐️ VACCINE ⭐️ OngoingThe purpose of the Part A Phase 1 of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adult participants 18 to 49 years of age and 60 to 80 years of age. The purpose of Part B Phase 2 and Part C Phase 2 is to evaluate …
Results expected Sep 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:03 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
RSV booster study aims to keep seniors safe for five seasons
⭐️ VACCINE ⭐️ OngoingThe purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vac…
Results expected Sep 2026 (estimated)
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 31, 2026 00:00 UTC
GSK · GSK NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New malaria vaccine trial aims to block infection without causing illness
⭐️ VACCINE ⭐️ Recruiting nowThis is a randomized, double-blind, placebo-controlled Phase 1 trial of Plasmodium falciparum (Pf) sporozoite (SPZ) late-arresting replication-competent (LARC) malaria vaccine (PfSPZ-LARC2 Vaccine) administered to healthy, malaria-naive study participants in Germany by direct ven…
Results expected Sep 2026 (estimated)
Phase: PHASE1 • Sponsor: Sanaria Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:01 UTC
-
New vaccine aims to protect african children from deadly salmonella
⭐️ VACCINE ⭐️ OngoingThe purpose of this study is to evaluate the safety, reactogenicity, and immune response of the GlaxoSmithKline (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-generalized modules for membrane antigens (iNTS-GMMA) candidate vaccine against S. Ty…
Results expected Sep 2026 (estimated)
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:35 UTC
GSK · GSK NYSE Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
BioNTech launches first human test of mRNA herpes vaccine
⭐️ VACCINE ⭐️ OngoingThis exploratory trial will have three parts. Part A is a dose escalation part, Part B is an expanded safety and dose evaluation part, and Part C is a safety and immunogenicity evaluation part in individuals with recurrent HSV-2 genital herpes. Part A will focus on the safety ev…
Results expected Oct 2026 (estimated)
Phase: PHASE1 • Sponsor: BioNTech SE • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:55 UTC
BioNTech SE · BNTX NASDAQ Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Could a Plant-Based vaccine beat the flu?
⭐️ VACCINE ⭐️ OngoingThis Phase 1/2 study is intended to assess the safety, tolerability, and immunogenicity of recombinant TVLP in adults 18-64 and 65 years of age and above and to confirm the dose(s) to be developed further in these two age cohorts.
Results expected Oct 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Aramis Biotechnologies Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 06, 2026 00:00 UTC
-
Pregnancy vaccine shields newborns from RSV: Real-World data reveals impact
⭐️ VACCINE ⭐️ OngoingThis study will be conducted in collaboration with a research network of independent hospital sites to evaluate the vaccine effectiveness (VE) and impact of ABRYSVO vaccination during pregnancy in a real-world population over multiple seasons, which began in 2024 across Argentina…
Results expected Oct 2026 (estimated)
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:34 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New malaria vaccine trial aims to block the parasite at multiple stages
⭐️ VACCINE ⭐️ Recruiting nowThis is a Phase Ib age de-escalation, dose escalation, open-label study to assess the safety and immunogenicity of the multi-stage malaria vaccine candidate R21 plus RH5.1 and/or R78C in Matrix-M in adults aged 18-35 years and children aged 5-17 months in Burkina Faso.
Results expected Oct 2026 (estimated)
Phase: PHASE1 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 11:01 UTC
-
New nasal spray COVID-19 booster could replace needles
⭐️ VACCINE ⭐️ Recruiting nowThis Phase I/II trial in France evaluates safety and immunogenicity of a booster dose of an intranasal COVID-19 vaccine (LVT-001) versus a booster dose of a COVID-19 mRNA vaccine (Pfizer-BioNTech) in healthy adult volunteers. As a first-in-human trial, Phase I will assess the sa…
Results expected Oct 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:05 UTC
-
Could a Freeze-Dried vaccine shield all ages from hib?
⭐️ VACCINE ⭐️ OngoingThis trial is a randomized, partially blinded, positively controlled phase I clinical study. A total of 160 persons aged 18-59 years, 1-5 years, 6-11 months and 2 months (60-89 days) will be recruited into the trial, and the enrollment will be done according to the progression of…
Results expected Oct 2026 (estimated)
Phase: PHASE1 • Sponsor: CanSino Biologics Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 08, 2026 00:03 UTC
CanSino Biologics Inc. · 6185 HKEXReward if it works ModerateAiming at a cure or vaccine; success would transform the company.
Risk to the company ModerateA small company — one failure carries real weight.
-
Could this mRNA vaccine stop the virus behind mono and certain cancers?
⭐️ VACCINE ⭐️ OngoingThe main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to \<18-year-old healthy EBV-seronegative adole…
Results expected Oct 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Moderna launches first human test of mRNA vaccine against Epstein-Barr virus
⭐️ VACCINE ⭐️ OngoingThe purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.
Results expected Oct 2026 (estimated)
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 13, 2026 00:00 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New HIV vaccine trial aims to spark rare antibodies that could fight the virus
⭐️ VACCINE ⭐️ OngoingThis is a multicenter controlled interventional trial. This phase 1 trial is the first study to assess 426c.Mod.Core-C4b adjuvanted with 3M-052-AF + aluminum hydroxide suspension (Alum) in people living with HIV (PLWH).
Results expected Oct 2026 (estimated)
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:11 UTC
-
New meningitis vaccine for kids shows promise in large trial
⭐️ VACCINE ⭐️ OngoingThe goal of this clinical trial is to evaluate the immunogenicity and safety of an investigational group ACYW135 meningococcal conjugate vaccine in healthy children aged 2 to 6 years. The main questions it aims to answer are: Is the immune response induced by the investigationa…
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 12, 2026 00:00 UTC
Sinovac Biotech Co., Ltd. · SVA NASDAQReward if it works HighA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
Ebola survivors get vaccine booster to ward off return of the virus
⭐️ VACCINE ⭐️ OngoingThis study is a vaccine-related clinical trial which will be conducted by our study team at Kenema Government Hospital (KGH)'s Viral Hemorrhagic Fever Program in collaboration with Tulane University School of Medicine. This study is funded by Merck \& Co., the developers of ERVEB…
Results expected Nov 2026 (estimated)
Phase: PHASE4 • Sponsor: Tulane University • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:04 UTC
-
New Low-Dose tdap vaccine trial aims to boost protection with fewer side effects
⭐️ VACCINE ⭐️ Not yet recruitingThis is a randomized, double-blinded, parallel-controlled phase I/II clinical trial to evaluate the safety and preliminary immunogenicity of the Tetanus, Diphtheria and Acellular Component Pertussis Vaccine Adsorbed (reduced antigen content) in subjects aged 6 years and above.
Results expected Aug 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Institute of Medical Biology, Chinese Academy of Medical Sciences • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:06 UTC
-
Survivor stories aim to boost HPV shots in kids
⭐️ VACCINE ⭐️ Recruiting nowThis randomized controlled trial (RCT) evaluates the association of a narrative communication intervention on human papillomavirus (HPV) vaccination rates among 9- to 12-year-olds. The intervention is a brief video from local cancer survivors narrating their stories with an HPV-r…
Results expected Oct 2026 (estimated)
Phase: NA • Sponsor: Milton S. Hershey Medical Center • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:08 UTC
-
New vaccine aims to protect against common childhood illness
⭐️ VACCINE ⭐️ Not yet recruitingThis is a randomized, double-blinded, placebo-controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of the Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine in subjects ( aged 6 months to 59 years ).
Results expected Aug 2026 (estimated)
Phase: PHASE1 • Sponsor: Institute of Medical Biology, Chinese Academy of Medical Sciences • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:09 UTC
-
New nasal COVID vaccine could replace shots
⭐️ VACCINE ⭐️ OngoingA Double-blind, Randomized, Controlled, Phase 2a Study to Evaluate the Safety and Tolerability of a Newcastle Disease Virus-based Mucosal Vaccine (NDV-HXP-S-KP.2) Relative to an Approved Systemic mRNA Vaccine in Previously Vaccinated Adults
Results expected Sep 2026 (estimated)
Phase: PHASE2 • Sponsor: CastleVax Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
New Needle-Freeze? muscle shot chickenpox vaccine tested in toddlers
⭐️ VACCINE ⭐️ Recruiting nowThis study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection. It compares the GSK vaccines to Merck's chickenpox vaccine, administered just under the skin. Add…
Results expected Sep 2026 (estimated)
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:00 UTC
GSK · GSK NYSE Trade on eToro (ad)Reward if it works ModerateA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Can the HPV vaccine protect stem cell transplant patients?
⭐️ VACCINE ⭐️ OngoingThis phase IV trial studies how well Gardasil 9 vaccine works in preventing human papillomavirus (HPV) infection in patients with hematologic malignancies who are undergoing donor stem cell transplant. Vaccines, such as Gardasil 9, may help the body build an effective immune resp…
Results expected Sep 2026 (estimated)
Phase: PHASE4 • Sponsor: M.D. Anderson Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 18, 2026 00:00 UTC
-
New vaccine booster aims to shield against many coronaviruses
⭐️ VACCINE ⭐️ OngoingThe clinical trial is a phase1/2a, open-label, dose-escalating, multicentre trial evaluating the safety and immunogenicity of the CD40.Pan.CoV vaccine, adjuvanted or not, as a booster injection in adult participants in France. 48 participants divided into 4 cohorts will be includ…
Results expected Oct 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
-
New gold nanoparticle vaccine aims to outsmart COVID-19 variants
⭐️ VACCINE ⭐️ OngoingThis Phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of PepGNP-COVID19, a synthetic nanoparticle-based, T cell-priming peptide vaccine against SARS-CoV-2, when administered as a booster dose in healthy adults. PepGNP-COVID19 is designed to indu…
Results expected Oct 2026 (estimated)
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:33 UTC
-
5,000 volunteers tracked to see if chikungunya vaccine is safe
⭐️ VACCINE ⭐️ OngoingThis is an observational study with primary data collection, which will combine a prospective safety cohort study and an SCRI study.
Results expected Oct 2026 (estimated)
Sponsor: Valneva Austria GmbH • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 23, 2026 00:00 UTC
Valneva SE · VALN NASDAQ Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New RSV vaccine study aims to protect vulnerable patients
⭐️ VACCINE ⭐️ Recruiting nowThis clinical trial is being done to learn more about how well a vaccine (Arexvy®) for respiratory syncytial virus, also known as RSV, works in people with weakened immune systems. The main questions it aims to answer are: * Does 1 or 2 doses of Arexvy work better in people with…
Results expected Nov 2026 (estimated)
Phase: PHASE2 • Sponsor: Johns Hopkins University • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:03 UTC
Not investment advice. This page lists publicly registered clinical trials and the companies running them, for information only. A trial finishing is not a result, and a result is not an approval. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to a broker we have a commercial relationship with, and we may earn a commission if you open an account. This never affects which trials are listed or how they are ranked.